AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
5,049.00
-81.00 (-1.58%)
At close: 5:11PM GMT
Stock chart is not supported by your current browser
Previous close5,130.00
Open5,142.00
Bid5,030.00 x 6100
Ask5,250.00 x 13000
Day's range5,035.00 - 5,155.00
52-week range4,136.50 - 5,520.00
Volume2,331,853
Avg. volume2,056,921
Market cap63.919B
Beta0.63
PE ratio (TTM)18.10
EPS (TTM)279.00
Earnings date2 Feb 2018
Forward dividend & yield2.79 (4.51%)
Ex-dividend date2017-08-10
1y target est70.16
  • Reuters - UK Focus4 hours ago

    Positive Keytruda lung cancer data sends Merck shares up 6 pct

    Positive lung cancer results for Merck (Jakarta: 28586808.JK - news) & Co Inc's blockbuster drug Keytruda assuaged investor concerns about delays in testing and the withdrawal of an application for European use of the drug, sending the drugmaker's shares up more than 6 percent. A cocktail of immunotherapy Keytruda and two chemotherapy medicines helped lung cancer patients live longer and stopped the disease from advancing, early results from a study showed, Merck said.

  • Globe Newswire10 hours ago

    Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility

    Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today held an opening ceremony with AstraZeneca, at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate. The announcement follows the completion, in 2017, of both a large-scale, multi-purpose capacity expansion which also includes hydrogenation capabilities and a dedicated continuous flow production unit capable of producing multiple metric tons of high purity advanced intermediates per annum at the Karlskoga facility.

  • AstraZeneca's Lynparza Label Now Includes Breast Cancer
    Zacksyesterday

    AstraZeneca's Lynparza Label Now Includes Breast Cancer

    AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.

  • Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU
    Zacksyesterday

    Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU

    Global markets endured a volatile week, guided by opposing factors.

  • US OKs 1st drug aimed at women with inherited breast cancer
    Associated Press4 days ago

    US OKs 1st drug aimed at women with inherited breast cancer

    U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.

  • Reuters4 days ago

    U.S. FDA approves expanded use of AstraZeneca cancer drug

    The drug belongs to a class of drug known as PARP inhibitors that has already been used to treat advanced BRCA-mutated ovarian cancer, the FDA said. This is the first time a PARP inhibitor has been approved to treat breast cancer and the first time any drug has been approved to treat certain patients with metastatic breast cancer associated with the same genetic mutation.

  • Globe Newswire4 days ago

    Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast Cancer

    Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) approved BRACAnalysis CDx® for use as a companion diagnostic by healthcare professionals to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are candidates for treatment with the PARP inhibitor Lynparza (olaparib), marketed by AstraZeneca and Merck, known as MSD outside of the U.S. and Canada.  BRACAnalysis CDx is the first and only FDA-approved test for use in this indication.

  • Reuters - UK Focus4 days ago

    U.S. FDA approves expanded use of AstraZeneca cancer drug

    The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc (NYSE: AZN - news) 's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene. The drug belongs to a class of drug known as PARP inhibitors that has already been used to treat advanced BRCA-mutated ovarian cancer, the FDA said. This is the first time a PARP inhibitor has been approved to treat breast cancer and the first time any drug has been approved to treat certain patients with metastatic breast cancer associated with the same genetic mutation.

  • AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
    Zacks5 days ago

    AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

    AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.

  • AstraZeneca plc isn’t the only high-growth stock I’d buy today
    Fool.co.uk7 days ago

    AstraZeneca plc isn’t the only high-growth stock I’d buy today

    This stock could deliver high returns alongside AstraZeneca plc (LON: AZN).

  • The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez
    Zacks12 days ago

    The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez

    The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez

  • Globe Newswire13 days ago

    Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca

    Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that AstraZeneca will use the Company’s myChoice® HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).  Financial terms were not disclosed. Under the agreement, Myriad will use its myChoice HRD Plus test to evaluate patients enrolled in an ongoing Phase III trial.  In this collaboration, the companies will use the myChoice HRD Plus test to identify cases with homologous recombination deficiencies (HRD).

  • The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
    Zacks14 days ago

    The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

    The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

  • Reuters14 days ago

    New drug approvals hit 21-year high in 2017

    U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light -- more than double the previous year -- while the figure also rose in the European Union. The EU recommended 92 new drugs including generics, up from 81, and China laid out plans to speed up approvals in what is now the world's second biggest market behind the United States.

  • Reuters - UK Focus14 days ago

    New drug approvals hit 21-year high in 2017

    U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light -- more than double the previous year -- while the figure also rose in the European Union. The EU recommended 92 new drugs including generics, up from 81, and China laid out plans to speed up approvals in what is now the world's second biggest market behind the United States.

  • These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News
    Investor's Business Daily18 days ago

    These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News

    AstraZeneca and Novo Nordisk pulled upgrades on Friday as analysts looked ahead to key 2018 clinical trial readouts in ovarian cancer and diabetes.

  • 4 Large-Cap Pharma Stocks That Outperformed the S&P This Year
    Zacks18 days ago

    4 Large-Cap Pharma Stocks That Outperformed the S&P This Year

    We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.

  • Market Realist22 days ago

    What Analysts Recommend for AstraZeneca in December 2017

    Wall Street analysts estimate AstraZeneca (AZN) will report earnings per share (or EPS) of $0.71 on revenues of $6.0 billion during 3Q17, 4.4% growth as compared to revenues of $5.7 billion during 3Q16....

  • Market Realist22 days ago

    What Analysts Predict for AstraZeneca

    Wall Street analysts estimate the company to report EPS of $3.80 during 2017 as compared to the EPS of $4.31 during 2016.

  • Market Realist22 days ago

    How AstraZeneca’s Other Products Portfolio Performed in 3Q17

    AstraZeneca’s (AZN) other products portfolio includes various drugs for infections, neuroscience drugs, and gastrointestinal drugs.

  • Market Realist22 days ago

    AstraZeneca’s Respiratory Drugs: Pulmicort, Daliresp, and Tudorza

    In 3Q17, Tudorza generated revenues of $37.0 million, which reflected an ~21.0% decline on a YoY basis.

  • Why I’d buy Neil Woodford’s favourite dividend stock AstraZeneca plc in 2018
    Fool.co.uk24 days ago

    Why I’d buy Neil Woodford’s favourite dividend stock AstraZeneca plc in 2018

    2018 could be the year that AstraZeneca plc's (LON: AZN) turnaround finally starts to take hold.

  • Market Realist25 days ago

    How AstraZeneca’s CVMD Products Performed in 3Q17

    The CVMD segment reported revenues of $1.8 billion during 3Q17, a 4% decline in operating revenues driven by lower sales of Bydureon, Crestor, Onglyza, and Seloken.

  • Market Realist25 days ago

    How AstraZeneca’s Nexium, Synagis, and Losec Have Performed in 2017

    In 3Q17, AstraZeneca’s (AZN) Nexium generated revenues of $469.0 million, which reflected an ~9.0% decline on a year-over-year basis.

  • Market Realist25 days ago

    How AstraZeneca’s Duaklir and Bevespi Performed in 2017

    In 3Q17, Bevespi generated revenues of $4.0 million compared to $3.0 million in 2Q17.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes